Announced today that two posters will be presented at the American Association for Cancer Research Annual ...
Today announced the first patient dosed in the combination arm of the Phase 1/2 ABILITY (ABeta-only ...
Today announced initiation of enrollment in the combination arm of the Phase 1/2 ABILITY (ABeta-only ...
Announced that a poster presentation and an oral summary highlighting longer term follow up results ...
Received a Staff Delisting Determination from the Listing Qualifications Department of the NASDAQ Stock ...
Today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the ...
Will present preclinical results featuring its MDNA223 BiSKIT candidate at the 2023 AACR Special Conference ...
Announced today the appointment of Brent Meadows, MBA, as its Chief Business Officer, as part of the ...
Announced a clinical update on the monotherapy dose escalation portion of the first-in-human, Phase ...
Today announced financial results and corporate highlights for the first quarter ended June 30, 2023. ...